Practice Fusion inks deal with Theranos

'We are experiencing remarkable growth with enterprise partners'
By Erin McCann
10:50 AM
Share
Signing contract

One cloud-based EHR company has just inked its 600th partnership deal, one of the newest being with big-name clinical lab startup Theranos.

San Francisco-based Practice Fusion announced its most recent deals with Theranos and outpatient imaging company RadNet on Monday. The news comes less than two week after Practice Fusion announced big leadership changes after it brought in Tom Langan to take over as CEO.

Langan, who previously served as the company's chief commercial officer, pushed out former CEO Ryan Howard, who will now serve as board chair.

Earlier this month, the company also announced additional appointments, including bringing on a new audit chair as well.

Practice Fusion has "the potential to go public in the market," former CEO Ryan Howard told The Wall Street Journal this month. "We are preparing accordingly with all of the recent hires we have made," he said, referring to the company's appointment of Alan Black as board audit chair.

Practice Fusion has more than 470 integrate lab partner connections on its EHR platform, representing a 30 percent increase from last August. Some 150 health systems and hospital partners use the cloud-based EHR.

"We are experiencing remarkable growth with enterprise partners as they can leverage one seamless point of connection to integrate with our community of over 112,000 active healthcare professionals," Langan in  an Aug. 24 press statement announcing the new deals. "With nearly one million lab and imaging transmissions a month facilitated on the Practice Fusion platform, we are excited about the value that the Theranos and RadNet partnerships can help provide."

Through the new deals, docs on the Practice Fusion platform will be able to connect to more than 50 RadNet imaging centers in both California and New York. Docs will also be able to access "Theranos' innovative approach to lab testing," but when asked more specifically about what the Theranos deal means for the company and its providers, Practice Fusion officials did not respond for comment by publication time.